Document Detail


The North American Immune Tolerance Registry: practices, outcomes, outcome predictors.
MedLine Citation:
PMID:  11848456     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The North American Immune Tolerance Registry was initiated to study of immune tolerance (ITT) in Canada and the United States with respect to: 1) therapeutic regimens in use for haemophilia A (HA) and B (HB) inhibitor patients; 2) therapeutic outcomes; 3) potential predictors of successful outcome and 4) complications of therapy. Data on 188 ITT courses was collected by questionnaire from 60 haemophilia centers from 1993-99. Among the completed courses, the overall success rate was 70% (115/164) for all HA and 31% (5/16) for all HB. Outcome parameters noted to be predictive of ITT success for all HA were 1) pre-ITT induction (p = 0.003), 2) ITT peak (p = 0.007) and 3) historical pre ITT peak (p = 0.04) inhibitor titres. An inverse correlation between total daily dose (units/kg/day) and success: (80% with under 50; 71% with 50-99; 73% with 100-199; and 41% with > or = 200, p = 0.01) was found. Outcome predictors were not evaluable for HB, although adverse reactions to therapy, including nephrotic syndrome, and access complications were more common among failed courses. Infection most often complicated the use of access catheters. These results are discussed within the context of the international ITT registry and upcoming prospective ITT study.
Authors:
D M DiMichele; B L Kroner;
Related Documents :
19237516 - Variant-specific immunity to plasmodium berghei in pregnant mice.
7877526 - The role of cytokines in early detection of preeclampsia.
15176736 - Uterine mast cells: a new hypothesis to understand how we are born.
7802926 - The thymus in pregnancy: the interplay of neural, endocrine and immune influences.
17445806 - Triggering final oocyte maturation using different doses of human chorionic gonadotropi...
20230326 - The comparison of fetal behavior in high risk and normal pregnancies assessed by four d...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Thrombosis and haemostasis     Volume:  87     ISSN:  0340-6245     ISO Abbreviation:  Thromb. Haemost.     Publication Date:  2002 Jan 
Date Detail:
Created Date:  2002-02-18     Completed Date:  2002-08-27     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7608063     Medline TA:  Thromb Haemost     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  52-7     Citation Subset:  IM    
Affiliation:
New York Presbyterian Hospital, Weill Medical of College of Cornell, New York 10021, USA. dmdimich@med.cornell.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Canada / epidemiology
Catheterization, Central Venous / adverse effects
Cohort Studies
Comorbidity
Desensitization, Immunologic* / statistics & numerical data,  utilization
Factor IX / immunology*,  therapeutic use
Factor VIII / immunology*,  therapeutic use
Female
HIV Infections / epidemiology,  immunology
Hemophilia A / epidemiology,  immunology*,  therapy
Hemophilia B / epidemiology,  immunology*,  therapy
Hemorrhage / etiology
Humans
Immune Tolerance*
Immunization
Isoantibodies / blood,  immunology*
Male
Outcome Assessment (Health Care)
Questionnaires
Recombinant Proteins / immunology,  therapeutic use
Registries / statistics & numerical data*
Retrospective Studies
Treatment Outcome
United States / epidemiology
Chemical
Reg. No./Substance:
0/Isoantibodies; 0/Recombinant Proteins; 9001-27-8/Factor VIII; 9001-28-9/Factor IX

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  FV HR2 haplotype as additional inherited risk factor for deep vein thrombosis in individuals with a ...
Next Document:  Plasma protein oxidation is associated with an increase of procoagulant markers causing an imbalance...